[go: up one dir, main page]

EP1315838A2 - Procede de releve de profils de resistance de tissus et de lignees cellulaires - Google Patents

Procede de releve de profils de resistance de tissus et de lignees cellulaires

Info

Publication number
EP1315838A2
EP1315838A2 EP01980157A EP01980157A EP1315838A2 EP 1315838 A2 EP1315838 A2 EP 1315838A2 EP 01980157 A EP01980157 A EP 01980157A EP 01980157 A EP01980157 A EP 01980157A EP 1315838 A2 EP1315838 A2 EP 1315838A2
Authority
EP
European Patent Office
Prior art keywords
genes
expression
tissues
resistance
cell lines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01980157A
Other languages
German (de)
English (en)
Inventor
Ulrike Stein
Peter Michael Schlag
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Publication of EP1315838A2 publication Critical patent/EP1315838A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Definitions

  • the invention relates to a method for recording chemotherapy resistance profiles in human tumor tissue or tumor cell lines using real-time PCR technology (can be carried out, for example, on the Light Cycler, Röche Diagnostics GmbH). These patient-individual resistance profiles are created on the basis of quantitatively determined expressions of resistance-relevant genes. You can then form the molecular biological rationale for the selection of suitable cytostatics in the respective tumor chemotherapy. In addition, the chances of success (response) of certain chemotherapeutic regimes can be forecast.
  • MDR multidrug resistance
  • ABSC transporters ATP-dependent transmembrane drug-efflux pumps
  • MDR-associated genes include the following genes coding for ABC transporters: the MDR1 gene (coding for P-glycoprotein), the genes MRP1, 2, 3, 4, 5, 6, 7 (coding for multidrug resistance) Proteins 1 to 7), and the gene BCRP / MXR / ABCP (encoded for an identical protein; different nomenclature due to simultaneous discovery by 3 different groups).
  • the main cytostatic spectrum of these transporters includes anthracyclines such as doxorubicin and daunorubicin, vinca alkaloids such as vincristine and vinblastine, epipodophyllotoxins such as etoposide, taxanes such as taxol, and mitoxantrone, but also the transport of, for example, nucleosides.
  • Vault The main component of the corresponding cell organelle (Vault) is the Lung Resistance Protein / Major Vault Protein LRP / MVP.
  • cytoplasmic proteins that are involved in the metabolism or detoxification of cytostatics: the enzymes glutathione-S-transferase (GST) and aldehyde dehydrogenase (ADH) via intracellular detoxification of cyclophosphamide resistance.
  • GST glutathione-S-transferase
  • ADH aldehyde dehydrogenase
  • Other cytostatics resistance are e.g. mediated via dihydrofolate reductase (DHFR; against methotrexate), via thymidylate synthase (against 5-fluorodeoxyuridine) or via tubilin (against Vinca alkaloids and taxol).
  • Nuclear gene products can also cause resistance to cytostatics.
  • the enzymes topoisomerase I (resistance to camptothecin) and II (to doxorubicin and etoposide) are involved in the repair of cytostatic-induced DNA damage, as well as methyltransferase (MGMT) and methylpurine glycosylase (MPG; both resistance to alkylating agents).
  • MGMT methyltransferase
  • MPG methylpurine glycosylase
  • the enzyme superoxide dismutase (MnSOD, resistance e.g. to anthracyclines) protects against oxidative DNA damage.
  • This group of resistance-causing nuclear gene products also includes the "DNA mismatch repair" genes, such as MLH1, MSH2 and MSH6, as well as PMS 1 and PMS2.
  • apoptosis-regulating genes eg Bcl-2, Bax
  • genes involved in cell cycle eg p53, MDM2
  • Standard techniques such as e.g. the Northern blotting method can be used.
  • PCR-based methods such as As a very complex and semi-quantitative PCR variant, MIMIC-PCR is not suitable for examining the expression of a panel of genes on a large number of tissues.
  • the densitometric evaluation of PCR products after gel electrophoretic separation is also difficult. Therefore, the method of real time RT-PCR should be used to quantify gene expression, e.g. on the Light Cycler (Röche Diagnostics GmbH).
  • Cryosections are made from the biopsies or resectates that are shock-frozen directly in the OR for expression analysis. Since the microdissection method is generally used, the cryosections of each tissue are assessed by a pathologist in order to microdissectively target tumor cell populations or normal tissue. This procedure offers the advantage of comparing the subsequent expression analyzes of defined malignant tissue and normal tissue (eg both cell areas from the same section). The total cellular RNA is then isolated from these microdissected tissues. Expression analysis at the mRNA level is carried out using the Light Cycler System with real time RT-PCR and 50 ng total cellular RNA according to the manufacturer's protocol.
  • the amplificates can be detected either by the intercalation of a fluorescent dye (SYBR Green) or by using fluorescence-labeled oligos that hybridize between the primers to be detected in a sequence-specific manner.
  • the quantification takes place via gene-specific transcripts, which were carried out in serial dilution series (mostly 10 8 , 10 7 , 10 6 , 10 5 ). These transcripts were produced by cloning the corresponding gene-specific cDNA or fragments thereof into special plasmids (for example with SP6, T3 or T7 promoters for the corresponding DNA-dependent RNA polymerases).
  • the quality control of the PCR fragments obtained vs. primer Dimers are carried out using melting point analysis. Visual control can be performed using conventional gel electrophoresis.
  • control cell lines are included in the evaluation of the expression levels of the MDR genes in the tumors. These human cell lines are available as parent lines and as chemoresistant variants. Overexpression e.g. Certain resistance genes are characterized on both expression levels: on the RNA level using real time RT-PCR, and on the protein level using FACScan analysis with monoclonal antibodies. Functional parameters are also recorded, e.g. in the adriamycin accumulation assay and in the rhodamine influx / efflux assay. These characterizations form the basis for evaluating gene expressions in human tissues or cell lines, since RNA of the corresponding cell line pair is carried as a positive control in each RT-PCR run.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'efficacité d'une chimiothérapie de maladies malignes est souvent limitée par des résistants aux cytostatiques employés, initiés par une pluralité de mécanismes différents apparaissant parallèlement ou séquentiellement. La présente invention concerne l'utilisation d'un procédé de relevé de profils de résistance au moyen d'ARN de tissus ou de lignées cellulaires par l'intermédiaire de la méthode PCR-CDNA en temps réel (pouvant par exemple être mise en oeuvre sur le </= Light Cycler >/= de Roche Diagnostics). Ainsi, il est possible de détecter quantitativement les expressions de différents gènes impliqués dans la création, le renforcement ou la réduction de résistants. Par conséquent, il est possible de déterminer des profils de résistance individuels pour chaque patient, constituant la base biologique moléculaire pour le choix de cytostatiques adaptés, avant voire pendant la chimiothérapie tumorale correspondante. Par ailleurs, il est possible d'évaluer de manière pronostique les chances de réussite (réponse) de régimes chimiothérapiques définis.
EP01980157A 2000-09-01 2001-09-03 Procede de releve de profils de resistance de tissus et de lignees cellulaires Ceased EP1315838A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10043591A DE10043591A1 (de) 2000-09-01 2000-09-01 Verfahren zur Erfassung von Resistenz-Profilen von Geweben und Zellinien
DE10043591 2000-09-01
PCT/DE2001/003323 WO2002018630A2 (fr) 2000-09-01 2001-09-03 Procede de releve de profils de resistance de tissus et de lignees cellulaires

Publications (1)

Publication Number Publication Date
EP1315838A2 true EP1315838A2 (fr) 2003-06-04

Family

ID=7654966

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01980157A Ceased EP1315838A2 (fr) 2000-09-01 2001-09-03 Procede de releve de profils de resistance de tissus et de lignees cellulaires

Country Status (4)

Country Link
US (1) US20040058352A1 (fr)
EP (1) EP1315838A2 (fr)
DE (1) DE10043591A1 (fr)
WO (1) WO2002018630A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040156743A1 (en) * 2002-08-28 2004-08-12 Eric Bornstein Near infrared microbial elimination laser system
US7713294B2 (en) 2002-08-28 2010-05-11 Nomir Medical Technologies, Inc. Near infrared microbial elimination laser systems (NIMEL)
US20040126272A1 (en) * 2002-08-28 2004-07-01 Eric Bornstein Near infrared microbial elimination laser system
US7470124B2 (en) * 2003-05-08 2008-12-30 Nomir Medical Technologies, Inc. Instrument for delivery of optical energy to the dental root canal system for hidden bacterial and live biofilm thermolysis
US20050147978A1 (en) * 2003-12-30 2005-07-07 Jose Remacle Method for quantitative determination of multi-drug resistance in tumors
WO2005078100A1 (fr) * 2004-02-13 2005-08-25 Bml, Inc. Procédé de détection d'une cellule cancéreuse acquérant de la résisitance aux médicaments
JP2009502258A (ja) * 2005-07-21 2009-01-29 ノミール・メディカル・テクノロジーズ・インコーポレーテッド 標的部位の生物学的汚染物質のレベルを下げる方法
US20070071762A1 (en) * 2005-09-21 2007-03-29 Ccc Diagnostics, Llc Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac)
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
BRPI0711011A2 (pt) * 2006-05-18 2011-08-23 Molecular Profiling Inst Inc método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença
US20100113299A1 (en) * 2008-10-14 2010-05-06 Von Hoff Daniel D Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
JP2012517238A (ja) * 2009-02-11 2012-08-02 カリス エムピーアイ インコーポレイテッド 腫瘍の分子プロファイリング法
DE102017110966A1 (de) 2017-05-19 2018-11-22 Renk Aktiengesellschaft Getriebe insbesondere für Windkraftgeneratoren

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832653A1 (fr) * 1996-09-20 1998-04-01 Max-Delbrück-Centrum Für Molekulare Medizin Utilisation de cytokines en de composés cytotoxiques dans une méthode de traitement des tumeurs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0218630A2 *

Also Published As

Publication number Publication date
WO2002018630A3 (fr) 2002-11-21
US20040058352A1 (en) 2004-03-25
WO2002018630A2 (fr) 2002-03-07
DE10043591A1 (de) 2002-03-14

Similar Documents

Publication Publication Date Title
DE112005002742B4 (de) Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
DE60030281T2 (de) Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen
WO2002018630A2 (fr) Procede de releve de profils de resistance de tissus et de lignees cellulaires
WO2005085471A2 (fr) Procede et agent pour diagnostiquer de maniere differentielle des tumeurs de la glande thyroide
KR20170037095A (ko) 현미부수체 불안정성의 진단을 위한 pna 프로브를 이용한 융해곡선 분석방법, 및 이를 이용한 현미부수체 불안정성의 진단방법 및 현미부수체 불안정성의 진단용 키트
EP1366195B1 (fr) Procede de detection de molecules d&#39;acide nucleique
DE112008001164T5 (de) Gensignatur der frühen Hypoxie zur Vorhersage des Patientenüberlebens
DE102010043541B4 (de) Verfahren und Mittel zur Vorhersage der Überlebensdauer beim Pankreaskarzinom durch Analyse von Biomarkern
DE10038237A1 (de) Verfahren zum Nachweis von Mutationen in Nucleotidsequenzen
CN111763739B (zh) 一种肿瘤微卫星不稳定检测引物及其应用和试剂盒
DE102005052384B4 (de) Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
WO2003023059A2 (fr) Procede et necessaire destines au diagnostic ou au controle du traitement du cancer de l&#39;intestin
EP1409746A2 (fr) Methode et trousse de diagnostic ou de surveillance du traitement du cancer du sein
EP0571407B1 (fr) Clonage d&#39;un noveau membre de la famille des recepteurs des facteurs de croissance de fibroblastes (fgf)
DE102007051578B3 (de) Verfahren zur parallelen Amplifikation von wenigstens zwei verschiedenen Nukleinsäureabschnitten
US20190091259A1 (en) Selective Chemotherapy Treatments and Diagnostic Methods Related Thereto
KR100643146B1 (ko) 급성골수성 백혈병 환자의 예후를 판별하기 위한 디엔에이칩
DE102012215925B3 (de) Zeitgleicher Nachweis verschiedener microRNA-Biogenese-Formen
DE19733619C1 (de) CASE-PCR, ein hochselektives Verfahren zum Nachweis von Onkogenmutationen und Allelvarianten
DE102020111423B4 (de) MYH11/NDE1 Region als epigenetischer Marker für die Identifizierung von Endothel-Vorläuferzellen (EPCs)
DE102009047549B4 (de) Verfahren und Mittel zum patienten- und malignomspezifischen Nachweis von Malignomzellen
DE102005011003B4 (de) Verfahren und Mittel zur differentiellen Diagnose von Schilddrüsentumoren
EP1525477A2 (fr) Marqueurs moleculaires de carcinome cholangiocellulaire
WO2012052473A1 (fr) Procédé de diagnostic de tumeurs colorectales aneuploïdes
Kuczyk et al. The Prognostic Role of Alterations of the p53 Tumor Suppressor Gene in Superficial and Advanced Stage Bladder Cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030331

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

17Q First examination report despatched

Effective date: 20041220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20091226